Public domain

NIH Selects ICF to Provide Public Health Information Services

Retrieved on: 
Monday, September 28, 2020
Biological databases, Online databases, Information science, Databases, Science and technology in the United States, MedlinePlus, Public domain, PubMed, MEDLINE, ClinicalTrials.gov, Medical library, National Institutes of Health

FAIRFAX, Va., Sept. 28, 2020 /PRNewswire/ -- ICF (NASDAQ: ICFI), a global consulting and digital services provider, was recently awarded a new multiple-award blanket purchase agreement (BPA) to support the National Institutes of Health (NIH) in providing biomedical, public health, clinical and consumer health information services.

Key Points: 
  • FAIRFAX, Va., Sept. 28, 2020 /PRNewswire/ -- ICF (NASDAQ: ICFI), a global consulting and digital services provider, was recently awarded a new multiple-award blanket purchase agreement (BPA) to support the National Institutes of Health (NIH) in providing biomedical, public health, clinical and consumer health information services.
  • ICF's team of public health, IT and cybersecurity specialists along with their librarians, biostatisticians, trainers and other experts will provide expansive support services to NLM programs and its many databases, tools and services, including PubMed, Bookshelf, MedlinePlus and ClinicalTrials.gov.
  • "The world's largest biomedical library, NLM provides a valuable, reliable source for public health information to advance research and help the public better understanding critical health issues.
  • ICF's team of public health experts routinely translate science and health data into easy-to-understand findings and distributes this information to the people who need it most.

Global Cancer Generics Market Size Sales Demand Dominating the Branded Drug Status With US$ 55 Billion Future Opportunity By 2026

Retrieved on: 
Thursday, September 10, 2020
Articles, Health, Life sciences, Pharmaceutical industry, Pharmaceuticals policy, Generic drug, Public domain

Kuick Research Reports Highlights Ongoing Commercial Opportunities, Regional Trends & Comprehensive Clinical Insight On 43 Cancer Generics Available In The market

Key Points: 
  • Kuick Research Reports Highlights Ongoing Commercial Opportunities, Regional Trends & Comprehensive Clinical Insight On 43 Cancer Generics Available In The market
    NEW DELHI, Sept. 10, 2020 /PRNewswire/ -- "Global Cancer Generics Market, Drug Dosage, Price & Opportunity Insight 2026" Report Highlights:
    Global Cancer Generics Market Opportunity: > USD 55 Billion By 2026
    Global Generics Market Growth 2018-2026: > 130%
    Global Cancer Generics Market Growth 2018-2026: 200%
    Comprehensive Insight On Cancer Generics Drugs: 43 Generics
    For Cell Therapy, Gene Therapy, Vaccine, Antibodies, Oncology Market & Clinical Pipeline Reports Visit: https://www.kuickresearch.com/page-Pharmaceutical%20and%20Healthcare.php
    Amid the growth in terms of revenue and size that pharmaceutical market is experiencing, a significant contribution is laid down by the arrival of cancer generic drugs in the market.
  • The market is also responsible for upending the traditional forms of the cancer treatments and the engaged process of pricing about the different cancer therapies available.
  • As per "Global Cancer Generics Market, Drug Dosage, Price & Opportunity Insight 2026" report, it is observed that the convergence that the market has observed from branded cancer drugs to generic cancer drugs is becoming very prominent and fulfilling in terms of trends and opportunities.
  • It is estimated that the growing cancer generics market will provide numerous growth opportunities to the stakeholders as well as the healthcare customers.

Global Cancer Generics Market Size Sales Demand Dominating the Branded Drug Status With US$ 55 Billion Future Opportunity By 2026

Retrieved on: 
Thursday, September 10, 2020
Articles, Health, Life sciences, Pharmaceuticals policy, Generic drug, Public domain, Pharmaceutical industry, Authorized generics, Dr. Reddy's Laboratories

NEW DELHI, Sept. 10, 2020 /PRNewswire/ -- "Global Cancer Generics Market, Drug Dosage, Price & Opportunity Insight 2026" Report Highlights:

Key Points: 
  • NEW DELHI, Sept. 10, 2020 /PRNewswire/ -- "Global Cancer Generics Market, Drug Dosage, Price & Opportunity Insight 2026" Report Highlights:
    Global Cancer Generics Market Opportunity: > USD 55 Billion By 2026
    Global Generics Market Growth 2018-2026: > 130%
    Global Cancer Generics Market Growth 2018-2026: 200%
    Comprehensive Insight On Cancer Generics Drugs: 43 Generics
    For Cell Therapy, Gene Therapy, Vaccine, Antibodies, Oncology Market & Clinical Pipeline Reports Visit: https://www.kuickresearch.com/page-Pharmaceutical%20and%20Healthcare.php
    Amid the growth in terms of revenue and size that pharmaceutical market is experiencing, a significant contribution is laid down by the arrival of cancer generic drugs in the market.
  • The market is also responsible for upending the traditional forms of the cancer treatments and the engaged process of pricing about the different cancer therapies available.
  • As per "Global Cancer Generics Market, Drug Dosage, Price & Opportunity Insight 2026" report, it is observed that the convergence that the market has observed from branded cancer drugs to generic cancer drugs is becoming very prominent and fulfilling in terms of trends and opportunities.
  • It is estimated that the growing cancer generics market will provide numerous growth opportunities to the stakeholders as well as the healthcare customers.

Osmotica to Present at 2020 Wells Fargo Virtual Healthcare Conference

Retrieved on: 
Wednesday, September 2, 2020
Articles, Life sciences, Generic drug, Pharmaceutical industry, Pharmaceuticals policy, Public domain, Industries

Osmotica Pharmaceuticals plc is a fully integrated biopharmaceutical company focused on the development and commercialization of specialty products that target markets with underserved patient populations.

Key Points: 
  • Osmotica Pharmaceuticals plc is a fully integrated biopharmaceutical company focused on the development and commercialization of specialty products that target markets with underserved patient populations.
  • Vertical Pharmaceuticals, LLC represents the Companys diversified branded portfolio and Trigen Laboratories, LLC represents the non-promoted products including complex generic formulations.
  • RVL Pharmaceuticals, Inc. is the Companys ophthalmic subsidiary supporting Upneeq (oxymetazoline hydrochloride ophthalmic solution), 0.1%.
  • Osmotica has operations in the United States, Argentina, and Hungary.

Visiongain publishes Generic Drugs Market 2020-2030 report

Retrieved on: 
Friday, August 28, 2020
Articles, Health, Pharmaceuticals policy, Pharmaceutical industry, Life sciences, Generic drug, Public domain, Pharmacy, Drug pricing, Prescription drug prices in the United States, Abbreviated New Drug Application

So, with the emergence of new generic markets, the competition for generic drugs is increasing because of which various regions and companies are competing to increase their sales of generic drugs in the market.

Key Points: 
  • So, with the emergence of new generic markets, the competition for generic drugs is increasing because of which various regions and companies are competing to increase their sales of generic drugs in the market.
  • Cost-effectiveness and increasing investments: The cost of generic drugs is quite cheap as compared to the brand-name drugs which have increased the sales of generic drugs in the market.
  • As the cost of these drugs is affordable so, many companies have started investing in manufacturing the generic drugs.
  • The 431-page report provides clear detailed insight into the generic drugs market.

Visiongain publishes Generic Drugs Market 2020-2030 report

Retrieved on: 
Friday, August 28, 2020
Articles, Health, Pharmaceuticals policy, Pharmaceutical industry, Life sciences, Generic drug, Public domain, Pharmacy, Drug pricing, Prescription drug prices in the United States, Abbreviated New Drug Application

So, with the emergence of new generic markets, the competition for generic drugs is increasing because of which various regions and companies are competing to increase their sales of generic drugs in the market.

Key Points: 
  • So, with the emergence of new generic markets, the competition for generic drugs is increasing because of which various regions and companies are competing to increase their sales of generic drugs in the market.
  • Cost-effectiveness and increasing investments: The cost of generic drugs is quite cheap as compared to the brand-name drugs which have increased the sales of generic drugs in the market.
  • As the cost of these drugs is affordable so, many companies have started investing in manufacturing the generic drugs.
  • The 431-page report provides clear detailed insight into the generic drugs market.

Analysis on the Impact of COVID-19- Generic Drugs Market 2020-2024 | Evolving Opportunities With Amgen Inc. and Dr. Reddys Laboratories Ltd. | Technavio

Retrieved on: 
Monday, August 24, 2020
Health, Pharmaceutical, Pharmaceuticals policy, Articles, Pharmaceutical industry, Life sciences, Generic drug, Public domain, Health

The global generic drugs market is expected to grow by USD 123.50 million as per Technavio.

Key Points: 
  • The global generic drugs market is expected to grow by USD 123.50 million as per Technavio.
  • In addition, rising M&A activities are anticipated to boost the growth of the generic drugs market.
  • Moreover, generic drugs comprise identical active ingredients with similar strength, stability, purity, efficacy, and safety of the branded drug.
  • Generic Drugs Market Type Outlook (Revenue, USD Million, 2020-2024)
    Generic Drugs Market Geography Outlook (Revenue, USD Million, 2020-2024)

Osmotica Pharmaceuticals plc to Provide Second Quarter 2020 Business and Financial Update and Presentation on Upneeq™ on August 11, 2020

Retrieved on: 
Friday, August 7, 2020
Life sciences, Articles, Industries, Generic drug, Pharmaceutical industry, Pharmaceuticals policy, Public domain, CNX Nifty

Osmotica Pharmaceuticals plcis a fully integrated biopharmaceutical company focused on the development and commercialization of specialty products that target markets with underserved patient populations.

Key Points: 
  • Osmotica Pharmaceuticals plcis a fully integrated biopharmaceutical company focused on the development and commercialization of specialty products that target markets with underserved patient populations.
  • The company has a diverse portfolio consisting of four promoted products and approximately 30 non-promoted products, several of which incorporate Osmoticas proprietary Osmodexdrug delivery system.RVL Pharmaceuticals, Inc.is the Companys ophthalmic subsidiary supporting UPNEEQ.Vertical Pharmaceuticals, LLCrepresents the Companys diversified branded portfolio andTrigen Laboratories, LLCrepresents the Companys non-promoted products, including complex generic formulations.
  • Osmotica has operations inthe United States,Argentina, andHungary.

Bangladesh Pharmaceutical Market 2020-2025 - Share of Generic Drugs Expected to Surpass 85% by 2025, Favoring Local Pharma Companies

Retrieved on: 
Thursday, July 23, 2020
Health, Articles, Pharmaceuticals policy, Generic drug, Public domain, Pharmaceutical industry, Medication, Pharmaceutical industry in China, Essential medicines policies

Share Of Local Pharmaceutical Companies: >90%

Key Points: 
  • Share Of Local Pharmaceutical Companies: >90%
    Share of Generics Drugs in Pharmaceutical Market: >75%
    Leading Drugs Market Insight by Availability, Dosage & Price Analysis
    Number of Ongoing Clinical Studies: > 300 Clinical Studies
    Biotech pioneers of the Bangladesh Pharmaceutical industry are considered as a valuable tool for the overall improvement and efficacy of the market.
  • To a surprise, Bangladesh pharmaceutical market had been largely dependent on the imports as well as on multinational companies for meeting the needs of the local population.
  • However, in recent times local pharmaceutical companies have emerged as the game-changer by contributing more than 90% of the overall available medicines in the market.
  • The share of generic drugs is expected to surpass 85% by the 2025, which will further strengthen the dominance of local pharmaceutical companies in the market.

Osmotica Pharmaceuticals plc to Present at Jefferies Virtual Optical Health Summit

Retrieved on: 
Tuesday, June 16, 2020
Pharmaceutical industry, Articles, Life sciences, Generic drug, Pharmaceuticals policy, Public domain, Pharmaceutical industry in India, Industries

The presentation will be webcast live at the aforementioned time, and archived for 30 days thereafter, via the Companys website at www.osmotica.com under the Investor & News section.

Key Points: 
  • The presentation will be webcast live at the aforementioned time, and archived for 30 days thereafter, via the Companys website at www.osmotica.com under the Investor & News section.
  • Osmotica Pharmaceuticals plc is a fully integrated biopharmaceutical company focused on the development and commercialization of specialty products that target markets with underserved patient populations.
  • Vertical Pharmaceuticals, LLC represents the Companys diversified branded portfolio and Trigen Laboratories, LLC represents the non-promoted products including complex generic formulations.
  • Osmotica has operations in the United States, Argentina, and Hungary.